ES2398528T3 - Moduladores del activador del factor de crecimiento de hepatocitos - Google Patents

Moduladores del activador del factor de crecimiento de hepatocitos Download PDF

Info

Publication number
ES2398528T3
ES2398528T3 ES05810858T ES05810858T ES2398528T3 ES 2398528 T3 ES2398528 T3 ES 2398528T3 ES 05810858 T ES05810858 T ES 05810858T ES 05810858 T ES05810858 T ES 05810858T ES 2398528 T3 ES2398528 T3 ES 2398528T3
Authority
ES
Spain
Prior art keywords
antibody
seq
hgfa
sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05810858T
Other languages
English (en)
Spanish (es)
Inventor
Daniel K. Kirchhofer
Yan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2398528T3 publication Critical patent/ES2398528T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES05810858T 2004-10-04 2005-10-03 Moduladores del activador del factor de crecimiento de hepatocitos Expired - Lifetime ES2398528T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61565704P 2004-10-04 2004-10-04
US615657P 2004-10-04
PCT/US2005/036300 WO2006042173A2 (en) 2004-10-04 2005-10-03 Modulators of hepatocyte growth factor activator

Publications (1)

Publication Number Publication Date
ES2398528T3 true ES2398528T3 (es) 2013-03-19

Family

ID=36148972

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05810858T Expired - Lifetime ES2398528T3 (es) 2004-10-04 2005-10-03 Moduladores del activador del factor de crecimiento de hepatocitos

Country Status (15)

Country Link
US (4) US20060147451A1 (https=)
EP (1) EP1809673B1 (https=)
JP (2) JP4937127B2 (https=)
KR (1) KR101252306B1 (https=)
CN (1) CN101035810B (https=)
AU (1) AU2005294146B2 (https=)
BR (1) BRPI0515670A (https=)
CA (1) CA2577598C (https=)
ES (1) ES2398528T3 (https=)
IL (1) IL181450A0 (https=)
NO (1) NO20072302L (https=)
NZ (1) NZ553327A (https=)
RU (1) RU2418004C2 (https=)
WO (1) WO2006042173A2 (https=)
ZA (1) ZA200701789B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0515670A (pt) 2004-10-04 2008-07-29 Genentech Inc anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met
US8088908B2 (en) * 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
AR065271A1 (es) * 2007-02-09 2009-05-27 Genentech Inc Anticuerpos anti-robo4 y sus usos
US20170204191A1 (en) * 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
US8759491B2 (en) * 2009-10-19 2014-06-24 Genentech, Inc. Modulators of hepatocyte growth factor activator
EP2491059B1 (en) 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
MX346500B (es) 2010-11-10 2017-03-22 Genentech Inc * Metodos y composiciones para inmunoterapia para enfermedad neural.
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2023172863A1 (en) * 2022-03-07 2023-09-14 Elixiron Immunotherapeutics (hong Kong) Limited Anti-cd36 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CA2102463A1 (en) * 1992-11-05 1994-05-06 Mitsubishi Chemical Corporation Protein and gene encoding said protein
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US7045602B2 (en) * 2000-12-05 2006-05-16 Mitsubishi Chemical Corporation Specific antibody directed to active hepatocyte growth factor activator and method for using the same
JP4090236B2 (ja) * 2000-12-05 2008-05-28 三菱化学株式会社 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
BRPI0515670A (pt) 2004-10-04 2008-07-29 Genentech Inc anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met

Also Published As

Publication number Publication date
US20130217862A1 (en) 2013-08-22
AU2005294146B2 (en) 2011-09-15
CN101035810B (zh) 2011-04-06
CN101035810A (zh) 2007-09-12
JP5554298B2 (ja) 2014-07-23
US20110098449A1 (en) 2011-04-28
WO2006042173A2 (en) 2006-04-20
JP4937127B2 (ja) 2012-05-23
NZ553327A (en) 2010-02-26
NO20072302L (no) 2007-06-28
RU2007116806A (ru) 2008-11-10
IL181450A0 (en) 2007-07-04
EP1809673A2 (en) 2007-07-25
CA2577598C (en) 2016-09-20
US20060147451A1 (en) 2006-07-06
JP2012025752A (ja) 2012-02-09
KR101252306B1 (ko) 2013-04-08
WO2006042173A3 (en) 2006-08-17
US7825221B2 (en) 2010-11-02
US8969528B2 (en) 2015-03-03
EP1809673B1 (en) 2012-11-28
CA2577598A1 (en) 2006-04-20
JP2008515918A (ja) 2008-05-15
BRPI0515670A (pt) 2008-07-29
RU2418004C2 (ru) 2011-05-10
HK1105006A1 (en) 2008-02-01
US8399629B2 (en) 2013-03-19
KR20070102470A (ko) 2007-10-18
AU2005294146A1 (en) 2006-04-20
ZA200701789B (en) 2008-11-26
US20090047291A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
US8969528B2 (en) Antibodies to hepatocyte growth factor activator
ES2384569T3 (es) Fragmentos de anticuerpos monovalentes útiles como agentes terapéuticos
ES2344793T3 (es) Antagonistas anti-cmet humanizados.
US8759491B2 (en) Modulators of hepatocyte growth factor activator
AU2011254032B2 (en) Modulators of Hepatocyte Growth Factor Activator
HK1105006B (en) Modulators of hepatocyte growth factor activator
MX2007003832A (en) Modulators of hepatocyte growth factor activator
HK1178180B (en) Modulators of hepatocyte growth factor activator
HK1100779B (en) Humanized anti-cmet antagonists